RegulatoryRegulatoryPHN-03022026-10-30 15:32 CT
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
Source · FDA press releases
TLDR
The FDA announced accelerated approval of Voceryq for adults with recurrent respiratory papillomatosis. The agency describes it as the first plasmid DNA-based immunotherapy approved for this condition.
01—Key points
- 01Voceryq contains doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd.
- 02The approval covers adults with recurrent respiratory papillomatosis.
- 03The excerpt provides no clinical trial results or safety findings.
Why it matters Editorial
The announcement concerns a plasmid DNA-based immunotherapy rather than any peptide in the provided list.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.